本帖最后由 老马 于 2012-1-13 21:20 编辑
" I( o. C7 U4 F& y+ p
5 r- s1 x) y& @爱必妥和阿瓦斯丁的比较# {. K: k; S/ e/ B0 z" S
1 p8 X; p% M. u
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/0 X8 X7 }6 T6 j- {0 E3 @
! A9 t/ {- k+ K
A- [" V1 W3 e) P) i9 jhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/9 c- C+ K' P! e2 ?- r
==================================================
4 N2 `8 i* }1 ~% E: L9 z1 O( NOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
# p% g$ G9 f5 R5 l0 K$ t8 _Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
- R# _* {! H# v) pResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
3 M4 f! C+ k; A9 w2 c5 M) T
|